[
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
    "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
    "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758142593,
      "headline": "Sector Update: Health Care Stocks Edge Higher Late Afternoon",
      "id": 136791560,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were edging up late Wednesday afternoon, with the NYSE Health Care Index up 0.2%",
      "url": "https://finnhub.io/api/news?id=5b81c93dd0d7e72ae2d8602cd25c11a3b1652c3ee98bd19ac99c9c1b3cb7a3eb"
    }
  },
  {
    "ts": null,
    "headline": "Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)",
    "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDAQ:GMAB) without assigning a price target. In its financial performance release for the first half of 2025, Genmab A/S (NASDAQ:GMAB) reported $1.640 billion in […]",
    "url": "https://finnhub.io/api/news?id=cc9c74b74f4912dbda32887f7dff4d3ee26b883b522cc0961f5602f4abc6af29",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758137234,
      "headline": "Bernstein Reiterates a Sell Rating on Genmab A/S (GMAB)",
      "id": 136791587,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Genmab A/S (NASDAQ:GMAB) is one of the best affordable biotech stocks to invest in now. In a report released on September 8, Justin Smith from Bernstein reiterated a Sell rating on Genmab A/S (NASDAQ:GMAB) without assigning a price target. In its financial performance release for the first half of 2025, Genmab A/S (NASDAQ:GMAB) reported $1.640 billion in […]",
      "url": "https://finnhub.io/api/news?id=cc9c74b74f4912dbda32887f7dff4d3ee26b883b522cc0961f5602f4abc6af29"
    }
  },
  {
    "ts": null,
    "headline": "GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years",
    "summary": "GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.",
    "url": "https://finnhub.io/api/news?id=54da60dbd99115be1f3d2eef397a4baacdab16620b18cf8a5a7526d046d222b0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758128160,
      "headline": "GSK to Invest $30B in U.S. R&D and Manufacturing Over 5 Years",
      "id": 136791564,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK commits $30B to U.S. R&D and manufacturing, with advanced AI-driven biopharma facilities set to expand jobs and innovation.",
      "url": "https://finnhub.io/api/news?id=54da60dbd99115be1f3d2eef397a4baacdab16620b18cf8a5a7526d046d222b0"
    }
  },
  {
    "ts": null,
    "headline": "Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory",
    "summary": "We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.’s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance. Protagonist Therapeutics (PTGX) presents a […]",
    "url": "https://finnhub.io/api/news?id=c91f6c697f20f6f60e5081e75b70d51727b8a493f9483e978f9ae5439b69fe18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758127535,
      "headline": "Protagonist Therapeutics, Inc. (PTGX): A Bull Case Theory",
      "id": 136789907,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "We came across a bullish thesis on Protagonist Therapeutics, Inc. on BiotechBonanza’s Substack by AnotherBio. In this article, we will summarize the bulls’ thesis on PTGX. Protagonist Therapeutics, Inc.’s share was trading at $59.68 as of September 11th. PTGX’s trailing and forward P/E were 81.75 and 26.39 respectively according to Yahoo Finance. Protagonist Therapeutics (PTGX) presents a […]",
      "url": "https://finnhub.io/api/news?id=c91f6c697f20f6f60e5081e75b70d51727b8a493f9483e978f9ae5439b69fe18"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Stories: Markets Await Fed Rate Decision; China Regulator Reportedly Bans Nvidia Chip Sales to Alibaba, ByteDance",
    "summary": "The Dow Jones Industrial Average was up in late-morning trading Wednesday, while the S&P 500 and the",
    "url": "https://finnhub.io/api/news?id=92e7819956936be5ddd6f41a147bdcafd01cabc0218f4a4b06c6cf4c2a7f748f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758127461,
      "headline": "Top Midday Stories: Markets Await Fed Rate Decision; China Regulator Reportedly Bans Nvidia Chip Sales to Alibaba, ByteDance",
      "id": 136789824,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The Dow Jones Industrial Average was up in late-morning trading Wednesday, while the S&P 500 and the",
      "url": "https://finnhub.io/api/news?id=92e7819956936be5ddd6f41a147bdcafd01cabc0218f4a4b06c6cf4c2a7f748f"
    }
  },
  {
    "ts": null,
    "headline": "LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?",
    "summary": "Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.",
    "url": "https://finnhub.io/api/news?id=1211b38b2609d7a320cf421a4242040d461a680f00716c0954ebe130a8e4e929",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758126120,
      "headline": "LLY's $5B Virginia Plant Plan: Will U.S. Manufacturing Shift Pay Off?",
      "id": 136791566,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Eli Lilly will invest $5B in a new Virginia plant to make cancer drugs, creating 650 jobs amid Trump's tariff push.",
      "url": "https://finnhub.io/api/news?id=1211b38b2609d7a320cf421a4242040d461a680f00716c0954ebe130a8e4e929"
    }
  },
  {
    "ts": null,
    "headline": "Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats",
    "summary": "GSK (GSK), Eli Lilly (LLY), Johnson & Johnson (JNJ), and AstraZeneca (AZN) are among the pharmaceuti",
    "url": "https://finnhub.io/api/news?id=0391d40fd1d92ee20691e8302b10d5c911a6ae79c93fb6c88b523c8e6df64236",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758117040,
      "headline": "Market Chatter: Pharmaceutical Firms Pledge $350 Billion US Investment Amid Tariff Threats",
      "id": 136789010,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "GSK (GSK), Eli Lilly (LLY), Johnson & Johnson (JNJ), and AstraZeneca (AZN) are among the pharmaceuti",
      "url": "https://finnhub.io/api/news?id=0391d40fd1d92ee20691e8302b10d5c911a6ae79c93fb6c88b523c8e6df64236"
    }
  },
  {
    "ts": null,
    "headline": "Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis",
    "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis. These data are being presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress.1 Additionally, new long-term 52-week data from the Phase 3 IC",
    "url": "https://finnhub.io/api/news?id=ac559ff67ba33b55904dc87cdadf37261569e9d07df5ddaa0cf874fe9b508819",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758114000,
      "headline": "Icotrokinra shows superiority to deucravacitinib in first reported head-to-head trials reinforcing promise of novel targeted oral peptide for treatment of plaque psoriasis",
      "id": 136789027,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE: JNJ) today announced new data from the Phase 3 ICONIC-ADVANCE 1 and 2 studies which assessed the superiority of icotrokinra, a first-in-class investigational targeted oral peptide that selectively blocks the IL-23 receptor, compared to deucravacitinib in patients with moderate-to-severe plaque psoriasis. These data are being presented at the 2025 European Academy of Dermatology and Venereology (EADV) Congress.1 Additionally, new long-term 52-week data from the Phase 3 IC",
      "url": "https://finnhub.io/api/news?id=ac559ff67ba33b55904dc87cdadf37261569e9d07df5ddaa0cf874fe9b508819"
    }
  },
  {
    "ts": null,
    "headline": "How Black Monday changed Wall Street forever",
    "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. What if one phone call told you the market was on fire? On Trader Talk, Kenny Polcari relives Black Monday with First Boston trader John Parasco, the 1987 crash that erased half a trillion dollars in hours. Hear how specialists begged for firm capital, hedge funds dumped portfolios alphabetically, and blue chips like Johnson & Johnson (JNJ) lost half their value in a single day. A raw inside floor account of chaos, fear, and survival when Wall Street stared into the abyss. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
    "url": "https://finnhub.io/api/news?id=c1ca832c00dba20e5000e8b772f67622a446c9224439e34b868d491a7d35fe7e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758106809,
      "headline": "How Black Monday changed Wall Street forever",
      "id": 136799545,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "You can catch Trader Talk on Apple Podcasts, Spotify, YouTube, or wherever you get your podcasts. What if one phone call told you the market was on fire? On Trader Talk, Kenny Polcari relives Black Monday with First Boston trader John Parasco, the 1987 crash that erased half a trillion dollars in hours. Hear how specialists begged for firm capital, hedge funds dumped portfolios alphabetically, and blue chips like Johnson & Johnson (JNJ) lost half their value in a single day. A raw inside floor account of chaos, fear, and survival when Wall Street stared into the abyss. Watch more episodes of Trader Talk here. Trader Talk with Kenny Polcari on Yahoo Finance delivers expert analysis and actionable insights, empowering you to navigate market volatility and secure your financial future. This post was written by Langston Sessoms.",
      "url": "https://finnhub.io/api/news?id=c1ca832c00dba20e5000e8b772f67622a446c9224439e34b868d491a7d35fe7e"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson announces positive results in psoriasis",
    "summary": "Johnson & Johnson announces new Phase 3 data on icotrokinra, an oral peptide targeting the IL-23 receptor, presented at the EADV 2025 congress.The ICONIC-ADVANCE 1 and 2 studies demonstrate its...",
    "url": "https://finnhub.io/api/news?id=6c9b74a8f8a724edb05cf7bc5c08b78a5b8463353c214e33f66d48bf0244525a",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758103426,
      "headline": "Johnson & Johnson announces positive results in psoriasis",
      "id": 136788862,
      "image": "",
      "related": "JNJ",
      "source": "Finnhub",
      "summary": "Johnson & Johnson announces new Phase 3 data on icotrokinra, an oral peptide targeting the IL-23 receptor, presented at the EADV 2025 congress.The ICONIC-ADVANCE 1 and 2 studies demonstrate its...",
      "url": "https://finnhub.io/api/news?id=6c9b74a8f8a724edb05cf7bc5c08b78a5b8463353c214e33f66d48bf0244525a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson's New Psoriasis Pill Outperforms in Phase 3 Trials",
    "summary": "Johnson & Johnson's New Psoriasis Pill Outperforms in Phase 3 Trials",
    "url": "https://finnhub.io/api/news?id=a8137563438c88f360f6ce0f645a1b81ab28ad936bcabb7d4494ea6652eddc7b",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758098580,
      "headline": "Johnson & Johnson's New Psoriasis Pill Outperforms in Phase 3 Trials",
      "id": 136803731,
      "image": "",
      "related": "JNJ",
      "source": "MarketWatch",
      "summary": "Johnson & Johnson's New Psoriasis Pill Outperforms in Phase 3 Trials",
      "url": "https://finnhub.io/api/news?id=a8137563438c88f360f6ce0f645a1b81ab28ad936bcabb7d4494ea6652eddc7b"
    }
  },
  {
    "ts": null,
    "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
    "summary": "The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.",
    "url": "https://finnhub.io/api/news?id=73b9a38128f4de71fcb807dd3676ae230e993fe374b600e4d2c23aa40230f8a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1758067260,
      "headline": "GSK Says It Will Spend $30B on U.S. Manufacturing and R&D",
      "id": 136787474,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The U.K.-based firm and other drugmakers are seeking to avoid tariffs on drugs imported into the U.S.",
      "url": "https://finnhub.io/api/news?id=73b9a38128f4de71fcb807dd3676ae230e993fe374b600e4d2c23aa40230f8a6"
    }
  }
]